Biotech Catalysts This Week: 3 FDA Decisions, 3 Trial Completions and 15 Earnings Reports (Nov 8-15, 2026)

· 8 min read

Three PDUFA decisions converge on November 14, 2026, with SMMT, CYTK and BTAI all awaiting FDA action the same day, alongside BTAI’s November 10 earnings report. The week also carries 15 earnings reports and 10 new financing filings, while last week brought four delays, including VTVT, QURE, KRYS and SNDX, against eight newly announced timelines.

At a glance: this week 3 FDA decision dates, 3 Phase 2 or 3 trials reaching primary completion, 15 earnings reports and 10 new financing filings. Last week: 4 timelines pushed back, 8 new timelines announced and 12 key SEC filings.

🔄 What Changed Last Week

Timelines pushed back or discontinued, in the companies’ own words:

  • VTVT pushed back CATT1 from third quarter of 2026 to mid 2027. Before (2026-05-13): “The Company continues to advance its Phase 3 CATT1 trial, with enrollment on track for completion in the third quarter of 2026. vTv expects its current cash position to…” Now (2026-11-05): “In October 2026, the Company announced completion of enrollment in its Phase 3 CATT1 trial and continues to expect topline results in mid 2027, and randomized the first…” SEC filing
  • QURE pushed back AMT-260 from second quarter to first half of 2027. Before (2026-05-05): “In parallel, following a constructive interaction with the MHRA, we are preparing to submit an MAA in the third quarter and evaluating additional international…” Now (2026-11-04): “Continued clinical progress in pipeline programs AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE) · In the third quarter of 2026, the Company…” SEC filing
  • KRYS pushed back KB304 from 1H 2026 to in 2027. Before (2025-11-03): “Jeune Aesthetics, Inc. (Jeune), a wholly-owned subsidiary of the Company, remains on track to initiate a Phase 2 study of its lead program KB304 in 1H 2026 following…” Now (2026-11-02): “The Company expects to initiate a Phase 2 study of its lead program KB304 in 2027.” SEC filing
  • SNDX pushed back revumenib from second quarter of 2026 to fourth quarter of 2026. Before (2026-04-30): “New/updated data expected in the second quarter of 2026:” Now (2026-11-02): “The Company expects to have a major presence at upcoming medical meetings, with the presentation in the fourth quarter of 2026 of new/updated revumenib data including:” SEC filing

All pushed-back and discontinued milestones →

New timelines announced in press releases:

  • KARD, KATALYST-AV: in the second half of 2027. “Kardigan expects to provide an update on its Phase 3 development plans in the first half of 2027 and to report Week 48 topline data in the second half of 2027.” SEC filing
  • NERV, C19 Study: 2H 2027. “The topline data from Phase A is expected in 2H 2027.” SEC filing
  • IMCR, TEBE-AM: in the second quarter of 2027. “The trial is event-driven and topline overall survival data is expected in the second quarter of 2027.” SEC filing
  • ALGS, B-SUPREME: in late Q3 2027. “Topline data for both the HBeAg+ and HBeAg- cohorts are expected in late Q3 2027.” SEC filing
  • CATX, bamzireotide: first quarter of 2027. “We are incorporating these findings as a potential enrichment strategy into ongoing discussions with regulators on the design of a registration enabling study, and are targeting…” SEC filing
  • VOGX, mizagliflozin: second half of 2027. “The EMERGE study will be conducted at multiple centers in the United States, with topline results expected in the second half of 2027.” SEC filing
  • ENTX, Phase 3 study: late 2026. “Entera is preparing to activate the first clinical site for the Phase 3 study in late 2026, with topline results anticipated in the second half of 2028.” SEC filing
  • HELP, HLP003: Q4 2026. “As we continue to execute against upcoming milestones, their continued involvement at the Board level will be invaluable.” The Company continues to anticipate reporting topline…” SEC filing

📄 Key SEC Filings Last Week

Filings that can move a stock, each summarized from the filing itself; financing filings are under Dilution Watch below:

  • QNRX, 2026-11-06 (clinical trial): Quoin reported positive interim Phase 2/3 data for QRX003 in Netherton Syndrome, with the primary endpoint at p=0.0087 and the key secondary at p=0.0070, and raised up to $50.0 million in a private placement with $30.8 million upfront. Cash was $33.2 million at September 30, 2026. SEC filing
  • MSLE, 2026-11-06 (clinical trial): Satellos changed the primary efficacy endpoint of its BASECAMP Phase 2 pediatric DMD trial from dynamometry to change in MRI-measured vastus lateralis fat fraction after FDA feedback. Topline 12-week placebo-controlled data are expected in Q1 2027. SEC filing
  • KARD, 2026-11-06 (clinical trial): Completed enrollment in the Phase 2b KATALYST-AV trial of ataciguat in aortic stenosis, with 156 participants enrolled. Primary endpoint of aortic valve calcium moves to Week 48, and topline data is now expected in 2H 2027. Phase 3 plan update due 1H 2027. SEC filing
  • CATX, 2026-11-06 (clinical trial): Reported incremental Phase 1/2a data for VMT-α-NET at NANETS 2026: among 57 GEP-NET patients with all target lesions SSTR2-positive, PFS was 75% at 18 months, disease control 95%, and objective response 39%. Targeting an end-of-Phase 2 meeting in 1Q 2027. SEC filing
  • BRVE, 2026-11-06 (clinical trial): Braveheart Bio and Hengrui presented 52-week open-label extension data for HRS/BHB-1893 in oHCM at AHA 2026. Mean pVO2 rose 2.7 mL/kg/min and KCCQ-CSS rose 17.3 points, with 79% (33/42) of patients below a 30 mmHg Valsalva gradient at Week 52. SEC filing
  • PHAR, 2026-11-06 (regulatory): The UK MHRA approved Joenja (leniolisib) as the first treatment specifically for children with APDS in the U.K., according to a press release furnished as Exhibit 99.1. SEC filing
  • BCDA, 2026-11-06 (regulatory): Completed the clinical consultation process with Japan’s PMDA on CardiAMP Cell Therapy System for ischemic heart failure, advancing toward a marketing approval application. Completion does not constitute regulatory approval. Targets first Japan patients and commercial revenues in 2028. SEC filing
  • ASND, 2026-11-06 (regulatory): COMP adopted a positive opinion recommending maintenance of orphan designation for once-weekly TransCon CNP (navepegritide) for achondroplasia in children, providing 10 years of orphan market exclusivity upon final EC adoption. SEC filing
  • ONCO, 2026-11-06 (deal): Onconetix signed a First Amendment to its Share Exchange Agreement with Realbotix. If Net Cash is under $12.5 million and closing proceeds, the Seller will own 95% of Fully Diluted Shares. Net Cash now includes the Grid Promissory Note balance, and the End Date is extended to March 31, 2027. SEC filing
  • NXTC, 2026-11-06 (deal): NextCure and Avere Therapeutics agreed to a reverse merger in which Avere becomes a wholly owned subsidiary of NextCure, with Avere pre-closing financing of $320.0 million and an added $500.0 million raise at $27.6621 per share. SEC filing
  • ACRV, 2026-11-06 (deal): Acrivon acquired ACR-525, a Phase 2-ready oral JAK1 inhibitor, and a PKCθ inhibitor preclinical program from Aqilion AB for undisclosed cash, with no future milestone or royalty payments. Eosinophilic esophagitis is the first targeted indication. SEC filing
  • TPST, 2026-11-06 (listing): Tempest received a Nasdaq notice on November 4, 2026, that its stock closed below $1.00 for 30 consecutive business days. It has until May 3, 2027 to regain compliance, which requires 10 consecutive business days at or above $1.00. SEC filing

💊 FDA Decisions (PDUFA Dates)

Date Ticker Drug Indication Type
2026-11-14 SMMT ivonescimab EGFRm NSCLC post-TKI therapy BLA
2026-11-14 CYTK aficamten obstructive hypertrophic cardiomyopathy sNDA
2026-11-14 BTAI IGALMI agitation associated with bipolar disorders or schizophrenia sNDA

🧪 Phase 2 and 3 Trials Reaching Primary Completion

Estimated primary completion dates from ClinicalTrials.gov: the last patient reaches the main endpoint. Topline results usually follow weeks or months later.

  • ACHV, 2026-11-15 (Phase 3): Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes Registry
  • PGEN, 2026-11-11 (Phase 2): PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer Registry
  • PFE, 2026-11-12 (Phase 2): A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis Registry

📊 Earnings This Week

  • ADCT: 2026-11-09 (est. EPS -0.2219)
  • APGE: 2026-11-09 (est. EPS -1.1724)
  • ARTV: 2026-11-10 (est. EPS -0.5576)
  • SLS: 2026-11-10 (est. EPS -0.0505)
  • BTAI: 2026-11-10 (est. EPS -1.0302)
  • ATOS: 2026-11-10 (est. EPS -0.9639)
  • BFRI: 2026-11-10 (est. EPS -0.2244)
  • CNTB: 2026-11-10 (est. EPS -0.2754)
  • CADL: 2026-11-11 (est. EPS -0.3665)
  • ORIC: 2026-11-11 (est. EPS -0.3908)
  • OMER: 2026-11-11 (est. EPS 0.0306)
  • BCDA: 2026-11-11 (est. EPS -0.1326)
  • JAZZ: 2026-11-11 (est. EPS 5.2492)
  • CMPX: 2026-11-11 (est. EPS -0.1291)
  • ICU: 2026-11-11 (est. EPS -0.9343)

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • TECX: Phase 2 primary completion in 16 days, score 78/100
  • CRVO: Data readout guided for November 2026, window closes in 22 days, score 70/100
  • PYPD: FDA decision (NDA) in 20 days, score 66/100

💸 Dilution Watch: New Financing Filings

  • ZBIO: ATM program up to $200M (424B5, 2026-11-06) EDGAR
  • SXTP: private placement (8-K, 2026-11-06) EDGAR
  • SILO: private placement (8-K, 2026-11-06) EDGAR
  • RGEN: private placement (8-K, 2026-11-06) EDGAR
  • INO: underwritten offering (424B5, 2026-11-06) EDGAR
  • DTIL: underwritten offering (424B5, 2026-11-06) EDGAR
  • BIVI: private placement (8-K, 2026-11-06) EDGAR
  • ATYR: ATM program up to $215M (424B5, 2026-11-06) EDGAR
  • VSTM: shelf with ATM program up to $100M (S-3ASR, 2026-11-05) EDGAR
  • SCYX: shelf registration up to $200M (S-3, 2026-11-05) EDGAR

Full Dilution Watch table →

📉 Downside Radar: Trading Far Below a Recent Offering

Of biotech stocks 25% or more below their close on the day of a recent offering, 76% were lower 60 trading days later, median -29% (any biotech on a random day: 53% lower, median -2%). On the radar now:

  • GRML: $3.84, 68% below $11.85, its close on the day of its Sep 28 registered direct offering
  • BSEM: $1.13, 63% below $3.09, its close on the day of its Sep 30 private placement
  • SBFM: $2.71, 60% below $6.76, its close on the day of its Oct 9 registered direct offering
  • MEDS: $1.18, 55% below $2.63, its close on the day of its Oct 16 private placement
  • BKHA: $5.63, 54% below $12.19, its close on the day of its Sep 24 private placement
  • ICU: $1.88, 47% below $3.55, its close on the day of its Oct 5 private placement
  • TCRT: $1.74, 43% below $3.03, its close on the day of its Oct 13 private placement
  • BIAF: $2.71, 43% below $4.72, its close on the day of its Oct 9 private placement

Full Downside Radar and how it was tested →

📉 Downside Radar: Financing Pressure

12 months of cash or less, an ATM program, shelf or S-1 on file and no offering in 90 days. Of biotech stocks in this setup, 41% sold new shares within three months (10% of comparable stocks) and 69% were lower 60 trading days later, median -17%; with 6 months of cash or less, 51% and 73%. Shortest cash first:

  • CUE: about 2.6 months of cash (Jun 30 balance sheet), shelf registration filed Mar 16
  • MBRX: about 3.4 months of cash (Jun 30 balance sheet), ATM program filed Aug 21 (new this week)
  • NNVC: about 4.1 months of cash (Jun 30 balance sheet), ATM program filed Oct 21
  • BHVN: about 5.0 months of cash (Sep 30 balance sheet), shelf registration filed May 4
  • PRME: about 6.8 months of cash (Jun 30 balance sheet), shelf registration filed Nov 7
  • ELTX: about 7.1 months of cash (Jun 30 balance sheet), ATM program filed Mar 16
  • ATOS: about 8.1 months of cash (Jun 30 balance sheet), ATM program filed Feb 20
  • HYPD: about 8.2 months of cash (Jun 30 balance sheet), ATM program filed May 6

The financing-pressure list and how it was tested →

📈 Last Week’s Biggest Gainers

  • OBX +44.43% (volume 4.6x average)
  • KTTA +44.02% (volume 37.9x average)
  • LYEL +43.27% (volume 6.9x average)
  • RYTM +28.04% (volume 6.5x average)
  • ANVS +26.31% (volume 6.8x average)

Earlier weekly catalyst recaps →

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.